Is there a Mounjaro oral pill — and what are your options?

Why are people searching for a Mounjaro pill, and does one exist?

The question makes sense. Tirzepatide has produced some of the most striking weight-loss results seen in clinical trials, and plenty of people would prefer a tablet to an injection. In SURMOUNT-1, participants taking the 15 mg dose lost an average of around 20–21% of their body weight over 72 weeks, figures cited by NICE's appraisal of tirzepatide (TA1026) when recommending the medicine for NHS use. The appetite for an oral version of that is understandable.

The reality, for now, is that no oral tirzepatide product has been licensed anywhere in the world for weight management. Eli Lilly is running clinical trials on an oral form of tirzepatide, but those results have not been submitted to the MHRA, and approval timelines are not yet public. If you come across websites claiming to sell a Mounjaro tablet or oral tirzepatide drops, treat that as a serious red flag, you'd be looking at an unlicensed or counterfeit product, not a legitimate medicine.

What tirzepatide does come as in the UK is a pre-filled KwikPen, delivering a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm. You can read more about how the injection works and what the treatment involves on our Mounjaro overview.

So what is the oral GLP-1 option available in the UK right now?

On 11 June 2026, the MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer called SNAC) making the UK the first country in Europe to licence an oral GLP-1 medicine for weight management. This is meaningfully different from Mounjaro. Semaglutide targets only the GLP-1 receptor; tirzepatide activates both GLP-1 and GIP receptors, which is why the two medicines produce different results and carry different eligibility criteria.

The Wegovy tablet is taken once daily, first thing in the morning, on an empty stomach with a small amount of plain water. You then wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines. The dose escalates from 1.5 mg through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each level. Because the tablet is stored at room temperature, it removes the fridge requirement that the injection carries, a genuine practical difference for some people.

In the phase 3 OASIS 4 trial (307 adults, 64 weeks), participants taking the 25 mg tablet lost an average of around 13.6% of their body weight compared with around 2.4% in the placebo group, with higher losses seen among those who adhered fully to treatment. Our overview of the Mounjaro pill question looks at this comparison in more detail, and you can explore the broader oral tirzepatide research landscape if you want to understand where the science currently sits.

Does a tablet suit everyone the injection doesn't, and what affects the choice?

Needle anxiety is one of the most common reasons people ask about an oral alternative. It's a legitimate concern, and it's one our prescribers hear regularly. The Wegovy tablet addresses it. What it doesn't do is replicate tirzepatide's mechanism or its clinical trial results, the two medicines are compared, but not equivalent.

Eligibility also differs. Mounjaro's UK licence covers adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as hypertension, dyslipidaemia, or type 2 diabetes. The Wegovy tablet is licensed on similar terms. Neither eligibility threshold alone guarantees that a medicine is the right fit; a prescriber weighs your full medical picture, current medications, and any contraindications before making a recommendation. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, and this is factored into clinical assessments.

One practical point worth raising: the oral semaglutide tablet's absorption can be affected by other medicines taken at the same time, and the strict morning routine matters more here than with the injection. If you take other daily medications, that's a conversation to have at consultation stage. For context on what private treatment costs in the UK, pricing varies by dose and provider; what counts is that any legitimate price includes a genuine prescription from a qualified prescriber, not just a product in the post.

The injection, meanwhile, requires cold-chain storage. Mounjaro pens are kept refrigerated at 2–8°C; when yours arrives, it comes by tracked DPD delivery in plain, unbranded packaging, and from there it lives in the fridge until you're ready to use it each week. Some people find that routine easy; others prefer the simplicity of a tablet they keep on the bedside table.

What should you do if you want to explore your options?

The NHS patient information page on tirzepatide gives a clear overview of how Mounjaro works and what to expect. For oral semaglutide, the MHRA's June 2026 approval announcement is the authoritative source for what has actually been licensed and why.

If you are weighing injection versus tablet, or simply want to know which licensed weight-loss medicine you might be suitable for, a clinical consultation is the right starting point. Our prescribers review every consultation personally, the same day it's submitted, details of the full process and what's included are on the treatment overview. There is no obligation, and the consultation is free. You can also read about what oral tirzepatide options look like for UK patients, or look at the pill form question from a different angle if you're still deciding whether a tablet or injection is right for you.

Check your eligibility and speak to our clinical team when you're ready.

Check your eligibility with a free consultation.